

# Pilar Garrido

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5219529/pilar-garrido-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

157  
papers

8,153  
citations

29  
h-index

89  
g-index

209  
ext. papers

10,210  
ext. citations

3.9  
avg, IF

5.12  
L-index

#	Paper	IF	Citations
157	A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERA-VOLT registry.. <i>Journal of Thoracic Oncology</i> , <b>2022</b> ,	8.9	1
156	Response to Mobocertinib in a patient with advanced Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion after several therapies including Amivantamab. <i>Current Problems in Cancer Case Reports</i> , <b>2022</b> , 5, 100145	0.3	
155	Perception and Improvisation of Gender Climate in Oncology and Role of International and National Societies. <i>Indian Journal of Medical and Paediatric Oncology</i> , <b>2022</b> , 43, 004-007	0.2	0
154	Targeting KRAS in Non-Small Cell Lung Cancer.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 792635	5.3	1
153	Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies.. <i>ESMO Open</i> , <b>2021</b> , 6, 100281	6	1
152	Future care for long-term cancer survivors: towards a new model. <i>Clinical and Translational Oncology</i> , <b>2021</b> , 1	3.6	0
151	ALK Rearranged Non-Small Cell Lung Carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors. <i>Current Problems in Cancer Case Reports</i> , <b>2021</b> , 100124	0.3	
150	Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. <i>BMC Cancer</i> , <b>2021</b> , 21, 230	4.8	3
149	The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. <i>ESMO Open</i> , <b>2021</b> , 6, 100058	6	18
148	Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design. <i>Future Oncology</i> , <b>2021</b> , 17, 1459-1472	3.6	3
147	Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). <i>ESMO Open</i> , <b>2021</b> , 6, 100048	6	2
146	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , <b>2021</b> , 26, e1508-e1513	5.7	5
145	Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. <i>Lung Cancer</i> , <b>2021</b> , 155, 151-155	5.9	3
144	Screening for fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody. <i>Expert Review of Molecular Diagnostics</i> , <b>2021</b> , 21, 437-444	3.8	1
143	Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3079-3079	2.2	2
142	Impact of the COVID-19 pandemic on the care of cancer patients in Spain. <i>ESMO Open</i> , <b>2021</b> , 6, 100157	6	13
141	Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. <i>ESMO Open</i> , <b>2021</b> , 6, 100131	6	5

140	Acute anti-Ma2 paraneoplastic encephalitis associated to pembrolizumab: a case report and review of literature. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 3303-3311	4.4	0
139	LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. <i>Cancer Medicine</i> , <b>2021</b> , 10, 5878-5888	4.8	1
138	Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive -mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 992-1002	12.9	17
137	Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours. <i>Clinical and Translational Oncology</i> , <b>2021</b> , 23, 1529-1541	3.6	7
136	Management of Intracranial Metastases in EGFR-Mutated NSCLC: A Review of Literature following an Unusual Case Report. <i>Case Reports in Oncological Medicine</i> , <b>2021</b> , 2021, 5526809	0.9	
135	Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3391-3402	2.2	62
134	The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II. <i>ESMO Open</i> , <b>2021</b> , 6, 100199	6	9
133	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , <b>2020</b> , 21, 914-922	21.7	328
132	Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 2253-2263	3.6	5
131	Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. <i>Lung Cancer</i> , <b>2020</b> , 146, 6-11	5.9	5
130	Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer. <i>Lung Cancer</i> , <b>2020</b> , 142, 63-69	5.9	7
129	Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 149, 84-88	5.3	5
128	Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, LBA111-LBA111	2.2	27
127	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 989-1003	3.6	36
126	Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC). <i>Pulmonology</i> , <b>2020</b> , 26, 10-17	3.7	13
125	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology</i> , <b>2020</b> , 21, 271-282	21.7	454
124	Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study. <i>BMC Psychology</i> , <b>2020</b> , 8, 123	2.8	
123	Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1320-1335	10.3	121

122	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 823-834	3.6	14
121	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 759-771	3.6	10
120	Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1828-1838	8.9	22
119	An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. <i>Lung Cancer</i> , <b>2019</b> , 136, 74-79	5.9	11
118	Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 2120-2132	8.9	28
117	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 133, 163-166	5.3	19
116	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , <b>2019</b> , 134, 72-78	5.9	15
115	New oncologic emergencies: What is there to know about immunotherapy and its potential side effects?. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 66, 1-8	3.9	14
114	Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 305-312.e3	4.9	3
113	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys". <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	27
112	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 135, 74-77	5.3	9
111	Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review. <i>Respiratory Medicine Case Reports</i> , <b>2019</b> , 26, 310-314	1.2	17
110	Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). <i>Annals of Oncology</i> , <b>2019</b> , 30, iv134	10.3	6
109	Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 2015-2027	7.4	17
108	Tumor-associated macrophages: "Good cop-bad cop". <i>Cancer</i> , <b>2019</b> , 125, 1941-1942	6.4	0
107	Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 64-72	12.9	96
106	Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. <i>Annals of Oncology</i> , <b>2019</b> , 30, 290-296	10.3	29
105	High Frequency of Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features. <i>Cancers</i> , <b>2019</b> , 11,	6.6	17

104	Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , <b>2019</b> , 108, 120-128	7.5	33
103	Lung cancer in Spanish women: The WORLD07 project. <i>European Journal of Cancer Care</i> , <b>2019</b> , 28, e12941.4		3
102	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , <b>2018</b> , 4, 351-357	13.4	357
101	A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). <i>Lung Cancer</i> , <b>2018</b> , 120, 27-33	5.9	11
100	Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH. <i>Clinical and Translational Oncology</i> , <b>2018</b> , 20, 443-447	3.6	20
99	Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5543-5551	12.9	11
98	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 771-781	35.1	107
97	Nivolumab-induced pneumonitis complicated by cyst formation. <i>Lung Cancer</i> , <b>2018</b> , 122, 258-259	5.9	1
96	Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients. <i>Oncotarget</i> , <b>2018</b> , 9, 36929-36944	3.3	10
95	Aligning digital CD8 scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. <i>Histopathology</i> , <b>2018</b> , 72, 270-284	7.3	12
94	NUT midline carcinoma causing critical stenosis of the coronary arteries: CT demonstration. <i>Surgery</i> , <b>2018</b> , 163, 480-481	3.6	1
93	MA04.01 Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, S366	8.9	6
92	Modified SureSelect Target Enrichment Protocol for Illumina Multiplexed Sequencing of FFPE Samples. <i>Biological Procedures Online</i> , <b>2018</b> , 20, 19	8.3	3
91	Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 219-226	3.6	2
90	Tumor lysis syndrome in solid tumors: Clinical characteristics and prognosis. <i>Medicina Clínica</i> , <b>2017</b> , 148, 121-124	1	12
89	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 317, 1844-1853	27.4	211
88	P2.03b-031 Impact of PD-L1 Status on Clinical Response in SELECT-1: Selumetinib + Docetaxel in KRASm Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S952-S953	8.9	2
87	Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. <i>Cancer Investigation</i> , <b>2017</b> , 35, 358-365	2.1	5

86	Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 508-518	3.6	10
85	Should clinically meaningful outcomes in cancer be based on individual survival rather than median overall survival?. <i>Journal of Comparative Effectiveness Research</i> , <b>2017</b> , 6, 491-495	2.1	
84	Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup. <i>ESMO Open</i> , <b>2017</b> , 2, e000141	6	
83	Reflections on the Implementation of Low-dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 568-573	0.7	
82	Treating -mutant NSCLC: latest evidence and clinical consequences. <i>Therapeutic Advances in Medical Oncology</i> , <b>2017</b> , 9, 589-597	5.4	23
81	Reflections on the Implementation of Low-Dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 568-573	0.7	9
80	Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 1537-1542	3.6	4
79	Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 178-188.e4	4.9	1
78	Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 341-356	3.6	5
77	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 194-207	8.9	132
76	A consensus statement on the gender perspective in lung cancer. <i>Clinical and Translational Oncology</i> , <b>2017</b> , 19, 527-535	3.6	16
75	P1.04-001 Osimertinib with Ramucirumab or Necitumumab in Advanced T790M-positive EGFR-Mutant NSCLC: Preliminary Ph1 Study Results. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S1972	8.9	5
74	Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH. <i>Farmacia Hospitalaria</i> , <b>2017</b> , 41, 688-691	0.9	2
73	Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial. <i>Annals of Oncology</i> , <b>2016</b> , 27, vi583	10.3	6
72	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , <b>2016</b> , 27, 417-23	10.3	101
71	Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. <i>Patient Preference and Adherence</i> , <b>2016</b> , 10, 1-7	2.4	11
70	Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. <i>Anticancer Research</i> , <b>2016</b> , 36, 6647-6653	2.3	6
69	Afatinib-induced hypertrichosis of the eyelashes and eyebrows. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , <b>2016</b> , 82, 192-3	0.8	4

68	Patient involvement in clinical research: why, when, and how. <i>Patient Preference and Adherence</i> , <b>2016</b> , 10, 631-40	2.4	131
67	Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 553-8	7.3	6
66	Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology. <i>Advances in Therapy</i> , <b>2016</b> , 33, 2059-2068	4.1	6
65	Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer. <i>Archivos De Bronconeumologia</i> , <b>2016</b> , 52, 378-88	0.7	15
64	Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , <b>2015</b> , 17, 103-12	3.6	21
63	Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , <b>2015</b> , 88, 160-6	5.9	7
62	Actualizaci3n de las recomendaciones para la determinaci3n de biomarcadores en el carcinoma de pulm3n avanzado de c3lula no peque1a. Consenso Nacional de la Sociedad Espa1ola de Anatom3a Patol3gica y de la Sociedad Espa1ola de Oncolog3a M3dica. <i>Revista Espanola De Patologia</i> , <b>2015</b> , 48, 80-89	1.2	1
61	Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, 431-46	4.9	33
60	Prognostic factors in advanced gastric cancer after second-line treatment.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 201-201	2.2	
59	Do new cancer drugs offer good value for money? the perspective of oncologists, payers, patients, and general population. <i>Value in Health</i> , <b>2014</b> , 17, A327	3.3	
58	Atypical carcinoid tumours of the lung: prognostic factors and patterns of recurrence. <i>Thorax</i> , <b>2014</b> , 69, 648-53	7.3	34
57	Lung cancer in women: an overview with special focus on Spanish women. <i>Clinical and Translational Oncology</i> , <b>2014</b> , 16, 517-28	3.6	17
56	Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. <i>PLoS ONE</i> , <b>2014</b> , 9, e107200	3.7	49
55	Final overall survival (OS) results from a phase II study of pemetrexed (Pem) and cisplatin (Cis) with concurrent thoracic radiation (RT) after Pem-Cis induction in patients with unresectable locally advanced (LA) nonsquamous non-small cell lung cancer (NS-NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7533-7533	2.2	
54	Survival surrogates in gastric cancer after first- and second-line chemotherapy treatment: A Spanish retrospective study from one institution.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15019-e15019	2.2	
53	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. <i>Clinical and Translational Oncology</i> , <b>2013</b> , 15, 977-84	3.6	17
52	Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study. <i>Lung Cancer</i> , <b>2013</b> , 81, 84-90	5.9	22
51	State of the art of radiotherapy. <i>Translational Lung Cancer Research</i> , <b>2013</b> , 2, 189-99	4.4	1

50	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 239-46	21.7	3985
49	Recomendaciones para la determinaci3n de biomarcadores en el carcinoma de pulm3n no microc3nico avanzado. Consenso nacional de la Sociedad Espa3ola de Anatom3a Patol3gica y de la Sociedad Espa3ola de Oncolog3a M3dica. <i>Revista Espanola De Patologia</i> , <b>2012</b> , 45, 14-28	1.2	6
48	MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. <i>Lung Cancer</i> , <b>2012</b> , 76, 373-9	5.9	21
47	Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. <i>Clinical and Translational Oncology</i> , <b>2012</b> , 14, 820-6	3.6	1
46	Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). <i>Clinical and Translational Oncology</i> , <b>2012</b> , 14, 338-49	3.6	29
45	Functions and workload of medical oncologists in Spain. <i>Clinical and Translational Oncology</i> , <b>2012</b> , 14, 423-9	3.6	6
44	Lung adenocarcinoma <b>2012</b> , 136-165		
43	Consenso de la Sociedad Espa3ola de Anatom3a Patol3gica (SEAP) y de la Sociedad Espa3ola de Oncolog3a M3dica (SEOM) sobre la determinaci3n de HER2 en el carcinoma g3strico. <i>Revista Espanola De Patologia</i> , <b>2011</b> , 44, 32-48	1.2	3
42	First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. <i>Lung Cancer</i> , <b>2011</b> , 72, 84-91	5.9	35
41	Management of lung cancer-associated anaemia: the Spanish Lung Cancer Anaemia Survey (SLCAS). <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 328-34	3.6	4
40	Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions. <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 629-35	3.6	4
39	Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 636-51	3.6	14
38	Molecular and flow cytometry characterization during the follow-up of three simultaneous lymphoproliferative disorders: hairy cell leukemia, monoclonal B-cell lymphocytosis, and CD4(++)/CD8(+/- dim) T-large granular lymphocytosis--a case report. <i>Cytometry Part B - Clinical Cytometry</i> , <b>2011</b> , 80, 195-200	3.4	4
37	Long-term survival in a smoking caucasian male patient treated with gefitinib for spinal cord compression secondary to lung cancer. <i>Onkologie</i> , <b>2011</b> , 34, 326-8		3
36	Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2167-73	2.2	62
35	Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 733-40	21.7	213
34	SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. <i>Clinical and Translational Oncology</i> , <b>2010</b> , 12, 735-41	3.6	11
33	New molecular targeted therapies integrated with radiation therapy in lung cancer. <i>Clinical Lung Cancer</i> , <b>2010</b> , 11, 91-7	4.9	51



32	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). <i>Clinical and Translational Oncology</i> , <b>2009</b> , 11, 284-9	3.6	12
31	Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy. <i>Clinical Lung Cancer</i> , <b>2009</b> , 10, 180-6	4.9	18
30	9170 Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAIL (MO19390). <i>European Journal of Cancer, Supplement</i> , <b>2009</b> , 7, 557	1.6	4
29	Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2008</b> , 9 Suppl 2, S76-82	4.9	8
28	Evaluation of functional single nucleotide polymorphisms of different genes coding for the immunoregulatory molecules in patients with monoclonal large granular lymphocyte lymphocytosis. <i>Human Immunology</i> , <b>2008</b> , 69, 101-7	2.3	
27	Use of both internal thoracic arteries in diabetic patients. <i>Annals of Thoracic Surgery</i> , <b>2008</b> , 85, 690; author reply 690	2.7	0
26	Expanded cells in monoclonal TCR-alpha-beta+/CD4+/NKa+/CD8-/dim T-LGL lymphocytosis recognize hCMV antigens. <i>Blood</i> , <b>2008</b> , 112, 4609-16	2.2	48
25	C3-02: Randomized phase II trial using concomitant chemoradiation plus induction (I) or consolidation (C) chemotherapy (CT) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Mature results of the SLCG 0008 study. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S365	8.9	6
24	Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4736-42	2.2	87
23	Monoclonal TCR-Vbeta13.1+/CD4+/NKa+/CD8-/dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. <i>Blood</i> , <b>2007</b> , 109, 4890-8	2.2	59
22	Extra-adrenal pheochromocytoma involving the left atrium: an infrequent pathologic occurrence. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2006</b> , 132, 1460-1	1.5	1
21	Phase II study of irinotecan (cpt-11) and cisplatin (cddp) regimen (IP) with concurrent thoracic radiotherapy (TRT) in limited-stage small cell lung cancer (LS-SCLC). <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 7084-7084	2.2	3
20	Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. <i>Cancer</i> , <b>2003</b> , 97, 2180-6	6.4	87
19	Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. <i>Lung Cancer</i> , <b>2003</b> , 39, 201-7	5.9	12
18	Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. <i>Annals of Oncology</i> , <b>2003</b> , 14, 1549-54	10.3	7
17	Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen. <i>Gynecologic Oncology</i> , <b>2002</b> , 84, 368-73	4.9	19
16	A practical approach to the molecular biology of kidney diseases: from basic science to bed side. <i>Journal of Renal Care</i> , <b>2002</b> , 28, 79-83		
15	Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trial. <i>Clinical Lung Cancer</i> , <b>2000</b> , 1, 287-93	4.9	8

14	Phase II multi-institutional study of Irinotecan (CPT-11) and Cisplatin (CDDP) on a three-week schedule in patients with advanced non-small cell lung cancer (NSCLC). <i>European Journal of Cancer</i> , <b>1999</b> , 35, S259	7.5	3
13	Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. <i>Oncology</i> , <b>1997</b> , 54 Suppl 1, 30-7	3.6	6
12	Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1996</b> , 38, 191-4	3.5	4
11	Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. <i>Cancer</i> , <b>1996</b> , 78, 211-6	6.4	24
10	Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. <i>European Journal of Cancer</i> , <b>1995</b> , 31A, 2215-9	7.5	74
9	Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1995</b> , 36, 255-8	3.5	4
8	FLEP (5-fluorouracil, leucovorin, etoposide, cisplatin) in advanced gastric cancer. <i>European Journal of Cancer</i> , <b>1994</b> , 30A, 1733-4	7.5	1
7	Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group. <i>Annals of Oncology</i> , <b>1994</b> , 5, 323-7	10.3	8
6	Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer. Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1993</b> , 16, 310-4	2.7	3
5	Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo-controlled study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1992</b> , 15, 436-40	2.7	93
4	Non-small-cell lung cancer (NSCLC): chemotherapy in advanced disease. Our experience in ten years. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1992</b> , 15, 23-8	2.7	3
3	Antiemetic regimens in outpatients receiving cisplatin and non-cisplatin chemotherapy. A randomized trial comparing high-dose metoclopramide plus methylprednisolone with and without lorazepam. <i>Acta Oncologica</i> , <b>1991</b> , 30, 623-7	3.2	6
2	Bone marrow examination in small cell lung cancer--when is it indicated?. <i>Acta Oncologica</i> , <b>1991</b> , 30, 587-9	3.2	4
1	Phase II trial of cisplatin and tegafur (Ftorafur) as initial therapy in squamous-cell carcinoma of the head and neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1990</b> , 13, 312-4	2.7	6